MICHAEL VASCONCELLES - 30 Jan 2026 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Signature
/s/ Charles N. York II, as Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
30 Jan 2026
Net transactions value
$0
Form type
4
Filing time
30 Jan 2026, 17:18:48 UTC
Previous filing
18 Jun 2025
Next filing
18 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
VASCONCELLES MICHAEL Head of Research and Dev. 1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE /s/ Charles N. York II, as Attorney-in-Fact 30 Jan 2026 0001734755

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Stock Option (right to buy Common Stock) Award $0 +171,000 $0.000000 171,000 30 Jan 2026 Common Stock 171,000 $11.16 Direct F1
transaction DAWN Restricted Stock Units Award $0 +114,000 $0.000000 114,000 30 Jan 2026 Common Stock 114,000 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F3 The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4 RSUs do not expire; they either vest or are canceled prior to the vesting date.